Anti-Blood Cancer Technology
BioHuntress is making a significant progress on its first innovation, the development of a scientifically validated nature-inspired compound known as BG008 (Propolis/bee glue derived), that can provide immeasurable relief to those suffering from blood cancers, which if successful will generate regional economic growth in the Maritimes.
In North America, it is unfortunate that there are about 16.6 million cancer patients encompassing 1.4 million blood cancer patients. Annually, around US $162 billion is being spent on chemotherapy treatments such as Revlimid for these patients. If the target market of BioHuntress is 5% of the patients that sign-up for clinical trials, this will lead to an $8 billion dollars.
BioHuntress anti-blood cancer patents are well protected in national jurisdictions including Canada, the United States and India.
Cancer cells
Blood Cancer Cells | Untreated
Standard Chemodrug | Untreated
BG008 | Treated
Tests have shown no negative effects by BG008 on healthy/normal human bone marrow cells.
